Followers | 14 |
Posts | 1,650 |
Boards Moderated | 0 |
Alias Born | 11/01/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
He has been advertising on Instagram
I think you're right
I got a day job
To be more clear, I don't care
Free promo would be better. You somehow believe we can get free promo?
I'm not new here. I care about profit. I leave the ethics and laws up to the government.
I wonder if he reads the board. I post yesterday hoping for a promo and today it looks like we have one
This one http://www.investorideas.com/news/2017/biotech/06221NasalSpray.asp ? I honestly don't care what he does to get this thing moving as long as it works
June 22, 2017 (Investorideas.com Newswire) A San Diego-based pharmaceutical company that focuses on over-the-counter medications reported strong Q1/17 results and expects to begin marketing a nasal spray by the end of the year.
Innovus Pharmaceuticals Inc. (INNV:OTCQB), a rapidly growing, San Diego-based pharmaceutical company that focuses on over-the-counter (OTC) medications, reported Q1/17 earnings of $2.2 million, an 865% increase over Q1/16, and a 28.7% increase from Q4/16.
Ajay Tandon, an analyst with SeeThruEquity, noted that "1Q17 growth was driven by the strong performance from the company's expanded sales distribution, and an increase in the number of commercial products to 18. Innovus continues to benefit from the performance of in-licensed products from Beyond Human and its BTH® sales and marketing platform—with Vesele, Sensum+, UriVarx, Zestra, RecalMax and BHT representing the majority of revenues."
He also stated that "the results demonstrated continued sales execution and place the company well on its way towards its guidance for $10mn–$15mn for the full year as it expands sales channels for its portfolio of 18 commercial products." He noted that the company's gross margins "remained at attractive levels, at 79%, allowing the company to cash burn and target profitability. . .INNV ended the quarter with cash on hand of $2.4mn and total debt of $2.3mn, with its balance sheet benefitting from an equity offering in which INNV raised $3.8mn."
Tandon expects FlutiCare, a generic reformulation of Flonase nasal spray, to provide growth, calling its launch "a key event to watch for 2018. . .FlutiCare™ is a fluticasone propionate nasal spray for allergic and non-allergic rhinitis ("hay fever"/"stuffy nose"), which Innovus has estimated represents more than a $1 billion market opportunity; it is the leading nasal steroid prescribed in the US, with 40mn units sold since 2014."
He reiterated that Innovus expects FlutiCare to "generate $10-15mn in revenue in its first year of commercial operations following full US distribution. Key to this view is the broad distribution plans for Fluticare™. This includes distribution in over 20,000 U.S. retail stores, including Walgreens, CVS, Rite Aid, Kroger, Target, and Safeway. FlutiCare™ will also be sold in the company's Beyond Human Sales & Marketing Platform, which has access to ~3,000 newspapers and magazines reaching 20–30 million consumers per month, two million current subscribers, access to over 140 of its websites, online retailers and Amazon."
"If management is able to meet its guidance in 2017 for $10mn to $15mn in revenue, the company could be looking at a breakout year in 2018 with the addition of $10mn–$15mn from FlutiCare™," stated Tandon.
"Management also indicated that it is targeting cash flow breakeven by the end of the year, which would reduce additional dilution risk from share issuances. We are targeting $14.7mn in revenue for 2017E and $25mn for 2018E, respectively," noted Tandon.
SeeThruEquity has set a target price of $0.65 per share for Innovus. Shares are currently trading around $0.11.
"We see Innovus as a high-risk / high-reward investment opportunity in the OTC pharmaceuticals space with a differentiated business model focused on men and women's health and vitality. We see several potential catalysts for the company over the next six to nine months stemming from its outlook for robust growth, and the upcoming launch of Fluticare™, which is now set for 4Q17," concluded Tandon.
Read what other experts are saying about:
https://www.thelifesciencesreport.com/pub/co/7536
Disclosure:
1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She or members of her household own shares of the following companies mentioned in this article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are sponsors of Streetwise Reports: Innovus Pharmaceuticals Inc. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
Would be nice if we see the same action this Summer as last year.
Maybe another promo should do it?
Gotta say i'm jealous of the flippers but I still feel good holding this
Wow that's not good. I'm still holding but this may get ugly
$CRQE .0008s are up! BIG VOLUME
$CRQE here we go
sounds good
Waiting for an upcoming big deal or Q2
$TAUG whats happening?
The mute button works well
People are quietly picking up shares here?
well I can't sell if I wanted i'm using Etrade and don't have GMERD shares yet
My GMER sell order was cancelled last night
It was HDSI previously and that's wonderful this is working out well for you.
I never bought and never would buy just 230 shares of GMER. I never bought any shares of it. There was a name change but I don't know what it was before.
Well whatever the name was before there was a RS
Another RS???
yeah its bad I've been sitting next to a charger for about 30 minutes
2.5 mil shares traded wow the sky is falling
I didn't buy high
I'm typing from my phone but I'll send it later. I forget if she owns 49 or 51%
Wrong Christie is a co-owner
Assuming you're talking to me, investors.
My only guess why this doesn't drop more is people aren't actively watching it
Everyone? The board isn't as active anymore. I think most flippers are gone and most longs will be waiting for Q2 results
I bought back in the .000s I'm not in a rush
Pennyland is losing interest but not much selling.
We will have to wait for the real news
Maybe some people scrolled past all of Christie's climate change posts and noticed she has her own drink
anything happen?